Therefore, it is noteworthy that our therapy generally worked well with any tumor donor and across individual TIL-PDX mice of a given cohort (7 cohorts total with n = 20 saline control and n = 18 IL-15 stimulation + PD-1 blockade TIL-PDX-LUAD mice), given the expected genetic tumor heterogeneity within a single tumor and the human cancer patient population. The gene discussed is IL15; the disease is neoplasm.